Thomas Wierzba to Vaccination
This is a "connection" page, showing publications Thomas Wierzba has written about Vaccination.
Connection Strength
1.763
-
Kanungo S, Desai SN, Saha J, Nandy RK, Sinha A, Kim DR, Bannerjee B, Manna B, Yang JS, Ali M, Sur D, Wierzba TF. An Open Label Non-inferiority Trial Assessing Vibriocidal Response of a Killed Bivalent Oral Cholera Vaccine Regimen following a Five Year Interval in Kolkata, India. PLoS Negl Trop Dis. 2015 May; 9(5):e0003809.
Score: 0.483
-
Kanungo S, Desai SN, Nandy RK, Bhattacharya MK, Kim DR, Sinha A, Mahapatra T, Yang JS, Lopez AL, Manna B, Bannerjee B, Ali M, Dhingra MS, Chandra AM, Clemens JD, Sur D, Wierzba TF. Flexibility of oral cholera vaccine dosing-a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone. PLoS Negl Trop Dis. 2015 Mar; 9(3):e0003574.
Score: 0.476
-
Kim SH, Pezzoli L, Yacouba H, Coulibaly T, Djingarey MH, Perea WA, Wierzba TF. Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010. PLoS One. 2012; 7(1):e29116.
Score: 0.383
-
Kaljee LM, Pach A, Thriemer K, Ley B, Jiddawi M, Puri M, Ochiai L, Wierzba T, Clemens J, Ali SM. Desirability for a typhoid fever vaccine among rural residents, Pemba Island, Tanzania. Vaccine. 2013 Jun 24; 31(29):2994-9.
Score: 0.105
-
Ali M, Sur D, You YA, Kanungo S, Sah B, Manna B, Puri M, Wierzba TF, Donner A, Nair GB, Bhattacharya SK, Dhingra MS, Deen JL, Lopez AL, Clemens J. Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India. Clin Infect Dis. 2013 Apr; 56(8):1123-31.
Score: 0.103
-
Marks F, Nguyen TT, Tran ND, Nguyen MH, Vu HH, Meyer CG, You YA, Konings F, Liu W, Wierzba TF, Xu ZY. Effectiveness of the Viet Nam produced, mouse brain-derived, inactivated Japanese encephalitis vaccine in Northern Viet Nam. PLoS Negl Trop Dis. 2012; 6(12):e1952.
Score: 0.102
-
Dey A, Molodecky NA, Verma H, Sharma P, Yang JS, Saletti G, Ahmad M, Bahl SK, Wierzba TF, Nandy RK, Deshpande JM, Sutter RW, Czerkinsky C. Human Circulating Antibody-Producing B Cell as a Predictive Measure of Mucosal Immunity to Poliovirus. PLoS One. 2016; 11(1):e0146010.
Score: 0.031
-
Kar SK, Pach A, Sah B, Kerketta AS, Patnaik B, Mogasale V, Kim YH, Rath SB, Shin S, Khuntia HK, Bhattachan A, Puri MK, Wierzba TF, Kaljee LM. Uptake during an oral cholera vaccine pilot demonstration program, Odisha, India. Hum Vaccin Immunother. 2014; 10(10):2834-42.
Score: 0.027
-
Bhattacharya SK, Sur D, Ali M, Kanungo S, You YA, Manna B, Sah B, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Dhingra MS, Donner A, Nair GB, Lopez AL, Wierzba TF, Clemens JD. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2013 Dec; 13(12):1050-6.
Score: 0.027
-
You YA, Ali M, Kanungo S, Sah B, Manna B, Puri M, Nair GB, Bhattacharya SK, Convertino M, Deen JL, Lopez AL, Wierzba TF, Clemens J, Sur D. Risk map of cholera infection for vaccine deployment: the eastern Kolkata case. PLoS One. 2013; 8(8):e71173.
Score: 0.027